Survivin: A new target for anti-cancer therapy

Cancer Treatment Reviews

Volumn 35, Issue 7, 2009, Pages 553-562

  Ryan, Bríd M ^a   O'Donovan, Norma ^b   Duffy, Michael J ^c,d  

^a NATIONAL CANCER INSTITUTE   (United States)

^b DUBLIN CITY UNIVERSITY   (Ireland)

^c ST VINCENT S UNIVERSITY HOSPITAL   (Ireland)

^d UNIVERSITY COLLEGE DUBLIN   (Ireland)

Author keywords

BIRC5; Cancer; IAP; Survivin; Treatment

Indexed keywords

1 (2 METHOXYETHOXY) 2 METHYL 3 (2 PYRAZINYLMETHYL)NAPHTHO[2,3 D]IMIDAZOLE 4,9 DIONE; ALPHA TOCOPHEROL; ANTISENSE OLIGONUCLEOTIDE; CELECOXIB; DACLIZUMAB; DOCETAXEL; EM 1421; HEAT SHOCK PROTEIN 90 INHIBITOR; IMIDAZOLE DERIVATIVE; INTERLEUKIN 2; LY 2181308; NORDIHYDROGUAIARETIC ACID; PEPTIDE VACCINE; PNEUMOCOCCUS VACCINE; PREDNISONE; RESVERATROL; RIBOZYME; SELENIUM; SHEPHERDIN; SILIBININ; SMALL INTERFERING RNA; SULINDAC; SURVIVIN; SURVIVIN PEPTIDE VACCINE; TAMOXIFEN; TERAMEPROCOL; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ADENOMATOUS POLYP; APOPTOSIS; BLADDER CANCER; BONE MARROW TOXICITY; BREAST CANCER; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CANCER PREVENTION; CANCER RESISTANCE; CANCER STEM CELL; CELL CYCLE ARREST; CELL PROLIFERATION; CLINICAL TRIAL; COLON CANCER; COLORECTAL ADENOMA; COLORECTAL CANCER; DRUG EFFICACY; DRUG FEVER; DRUG SAFETY; DRUG TARGETING; FATIGUE; FEVER; GENE SILENCING; GLIOMA; HUMAN; INFECTION; KIDNEY CARCINOMA; LARGE CELL LYMPHOMA; LEUKEMIA; LIVER CELL CARCINOMA; LUNG NON SMALL CELL CANCER; LYMPHOMA; MELANOMA; MULTIPLE MYELOMA; NAUSEA; NONHODGKIN LYMPHOMA; NONHUMAN; PANCREAS CANCER; PARTIAL THROMBOPLASTIN TIME; PLASMACYTOMA; PROSTATE CANCER; REVIEW; SIDE EFFECT; SOLID TUMOR; STOMACH CANCER; STOMATITIS; TUMOR REGRESSION; TUMOR VASCULARIZATION; UPREGULATION; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX DYSPLASIA;

HUMANS; MICROTUBULE-ASSOCIATED PROTEINS; NEOPLASMS;

EID: 70350234507     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2009.05.003     Document Type: Review

References (174)

1. Altieri D.C. Survivin, cancer networks and pathway-directed drug discovery. Nat Rev Cancer 81 (2008) 61-70
2. Li F. Survivin study: what is the next wave?. J Cell Physiol 1971 (2003) 8-29
3. Duffy M.J., O'Donovan N., Brennan D.J., Gallagher W.M., and Ryan B.M. Survivin: a promising tumor biomarker. Cancer Lett 2491 (2007) 49-60
4. Pennati M., Folini M., and Zaffaroni N. Targeting survivin in cancer therapy. Expert Opin Ther Targets 124 (2008) 463-476
5. Hunter A.M., LaCasse E.C., and Korneluk R.G. The inhibitors of apoptosis (IAPs) as cancer targets. Apoptosis 129 (2007) 1543-1568
6. Schimmer A.D. Inhibitor of apoptosis proteins: translating basic knowledge into clinical practice. Cancer Res 6420 (2004) 7183-7190
7. Crook N.E., Clem R.J., and Miller L.K. An apoptosis-inhibiting baculovirus gene with a zinc finger-like motif. J Virol 674 (1993) 2168-2174
8. Deveraux Q.L., and Reed J.C. IAP family proteins - suppressors of apoptosis. Genes Dev 133 (1999) 239-252
9. Ambrosini G., Adida C., and Altieri D.C. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 38 (1997) 917-921
10. Verdecia M.A., Huang H., Dutil E., Kaiser D.A., Hunter T., and Noel J.P. Structure of the human anti-apoptotic protein survivin reveals a dimeric arrangement. Nat Struct Biol 77 (2000) 602-608
11. Chantalat L., Skoufias D.A., Kleman J.P., Jung B., Dideberg O., and Margolis R.L. Crystal structure of human survivin reveals a bow tie-shaped dimer with two unusual alpha-helical extensions. Mol Cell 61 (2000) 183-189
12. Mahotka C., Wenzel M., Springer E., Gabbert H.E., and Gerharz C.D. Survivin-deltaEx3 and survivin-2B: two novel splice variants of the apoptosis inhibitor survivin with different antiapoptotic properties. Cancer Res 5924 (1999) 6097-6102
13. Badran A., Yoshida A., Ishikawa K., et al. Identification of a novel splice variant of the human anti-apoptopsis gene survivin. Biochem Biophys Res Commun 3143 (2004) 902-907
14. Caldas H., Honsey L.E., and Altura R.A. Survivin 2alpha: a novel Survivin splice variant expressed in human malignancies. Mol Cancer 41 (2005) 11
15. Li F. Role of survivin and its splice variants in tumorigenesis. Brit J Cancer 922 (2005) 212-216
16. Sampath J., and Pelus L.M. Alternative splice variants of survivin as potential targets in cancer. Curr Drug Discov Technol 43 (2007) 174-191
17. Tamm I., Wang Y., Sausville E., et al. IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs. Cancer Res 5823 (1998) 5315-5320
18. Suzuki A., Ito T., Kawano H., et al. Survivin initiates procaspase 3/p21 complex formation as a result of interaction with Cdk4 to resist Fas-mediated cell death. Oncogene 1910 (2000) 1346-1353
19. Mirza A., McGuirk M., Hockenberry T.N., et al. Human survivin is negatively regulated by wild-type p53 and participates in p53-dependent apoptotic pathway. Oncogene 2117 (2002) 2613-2622
20. Zaffaroni N., Pennati M., Colella G., et al. Expression of the anti-apoptotic gene survivin correlates with taxol resistance in human ovarian cancer. Cell Mol Life Sci 598 (2002) 1406-1412
21. Azuhata T., Scott D., Griffith T.S., Miller M., and Sandler A.D. Survivin inhibits apoptosis induced by TRAIL, and the ratio between survivin and TRAIL receptors is predictive of recurrent disease in neuroblastoma. J Pediat Surg 418 (2006) 1431-1440
22. Wright M.E., Han D.K., and Hockenbery D.M. Caspase-3 and inhibitor of apoptosis protein(s) interactions in Saccharomyces cerevisiae and mammalian cells. FEBS Lett 4811 (2000) 13-18
23. Grossman D., Kim P.J., Blanc-Brude O.P., et al. Transgenic expression of survivin in keratinocytes counteracts UVB-induced apoptosis and cooperates with loss of p53. J Clin Invest 1087 (2001) 991-999
24. Yamamoto T., Manome Y., Nakamura M., and Tanigawa N. Downregulation of survivin expression by induction of the effector cell protease receptor-1 reduces tumor growth potential and results in an increased sensitivity to anticancer agents in human colon cancer. Eur J Cancer 3817 (2002) 2316-2324
25. Dean E.J., Ranson M., Blackhall F., Holt S.V., and Dive C. Novel therapeutic targets in lung cancer: inhibitor of apoptosis proteins from laboratory to clinic. Cancer Treat Rev 332 (2007) 203-212
26. Salvesen G.S., and Duckett C.S. IAP proteins: blocking the road to death's door. Nat Rev Mol Cell Biol 36 (2002) 401-410
27. Kobayashi K., Hatano M., Otaki M., Ogasawara T., and Tokuhisa T. Expression of a murine homologue of the inhibitor of apoptosis protein is related to cell proliferation. Proc Natl Acad Sci USA 964 (1999) 1457-1462
28. O'Connor D.S., Grossman D., Plescia J., et al. Regulation of apoptosis at cell division by p34cdc2 phosphorylation of survivin. Proc Natl Acad Sci USA 9724 (2000) 13103-13107
29. Li F., Ackermann E.J., Bennett C.F., et al. Pleiotropic cell-division defects and apoptosis induced by interference with survivin function. Nat Cell Biol 18 (1999) 461-466
30. Shin S., Sung B.J., Cho Y.S., et al. An anti-apoptotic protein human survivin is a direct inhibitor of caspase-3 and -7. Biochemistry 404 (2001) 1117-1123
31. Conway E.M., Pollefeyt S., Steiner-Mosonyi M., et al. Deficiency of survivin in transgenic mice exacerbates Fas-induced apoptosis via mitochondrial pathways. Gastroenterology 1232 (2002) 619-631
32. Banks D.P., Plescia J., Altieri D.C., et al. Survivin does not inhibit caspase-3 activity. Blood 9612 (2000) 4002-4003
33. Li C., Wu Z., Liu M., Pazgier M., and Lu W. Chemically synthesized human survivin does not inhibit caspase-3. Protein Sci 17 (2008) 1624-1629
34. Eckelman B.P., Salvesen G.S., and Scott F.L. Human inhibitor of apoptosis proteins: why XIAP is the black sheep of the family. EMBO Rep 710 (2006) 988-994
35. Dohi T., Beltrami E., Wall N.R., Plescia J., and Altieri D.C. Mitochondrial survivin inhibits apoptosis and promotes tumorigenesis. J Clin Invest 1148 (2004) 1117-1127
36. Marusawa H., Matsuzawa S., Welsh K., et al. HBXIP functions as a cofactor of survivin in apoptosis suppression. EMBO J 2211 (2003) 2729-2740
37. Xia F., and Altieri D.C. Mitosis-independent survivin gene expression in vivo and regulation by p53. Cancer Res 667 (2006) 3392-3395
38. Verhagen A.M., Ekert P.G., Pakusch M., et al. Identification of DIABLO, a mammalian protein that promotes apoptosis by binding to and antagonizing IAP proteins. Cell 1021 (2000) 43-53
39. Du C., Fang M., Li Y., Li L., and Wang X. Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition. Cell 1021 (2000) 33-42
40. Yang D., Welm A., and Bishop J.M. Cell division and cell survival in the absence of survivin. Proc Natl Acad Sci USA 10142 (2004) 15100-15105
41. Okada H., and Mak T.W. Pathways of apoptotic and non-apoptotic death in tumour cells. Nat Rev Cancer 48 (2004) 592-603
42. Vader G., Kauw J.J., Medema R.H., and Lens S.M. Survivin mediates targeting of the chromosomal passenger complex to the centromere and midbody. EMBO Rep 71 (2006) 85-92
43. Ruchaud S., Carmena M., and Earnshaw W.C. The chromosomal passenger complex: one for all and all for one. Cell 1312 (2007) 230-231
44. Ruchaud S., Carmena M., and Earnshaw W.C. Chromosomal passengers: conducting cell division. Nat Rev Mol Cell Biol 810 (2007) 798-812
45. Li F., and Altieri D.C. Transcriptional analysis of human survivin gene expression. Biochem J 344 Pt 2 (1999) 305-311
46. Caldas H., Jiang Y., Holloway M.P., et al. Survivin splice variants regulate the balance between proliferation and cell death. Oncogene 2412 (2005) 1994-2007
47. Noton E.A., Colnaghi R., Tate S., et al. Molecular analysis of survivin isoforms: evidence that alternatively spliced variants do not play a role in mitosis. J Biol Chem 2812 (2006) 1286-1295
48. Jeyaprakash A.A., Klein U.R., Lindner D., Ebert J., Nigg E.A., and Conti E. Structure of a Survivin-Borealin-INCENP core complex reveals how chromosomal passengers travel together. Cell 1312 (2007) 271-285
49. Velculescu V.E., Madden S.L., Zhang L., et al. Analysis of human transcriptomes. Nat Genet 234 (1999) 387-388
50. Aoki Y., Feldman G.M., and Tosato G. Inhibition of STAT3 signaling induces apoptosis and decreases survivin expression in primary effusion lymphoma. Blood 1014 (2003) 1535-1542
51. Sommer K.W., Schamberger C.J., Schmidt G.E., Sasgary S., and Cerni C. Inhibitor of apoptosis protein (IAP) survivin is upregulated by oncogenic c-H-Ras. Oncogene 2227 (2003) 4266-4280
52. Hoffman W.H., Biade S., Zilfou J.T., Chen J., and Murphy M. Transcriptional repression of the anti-apoptotic survivin gene by wild type p53. J Biol Chem 2775 (2002) 3247-3257
53. Zhang T., Otevrel T., Gao Z., et al. Evidence that APC regulates survivin expression: a possible mechanism contributing to the stem cell origin of colon cancer. Cancer Res 6124 (2001) 8664-8667
54. Koul D., Takada Y., Shen R., Aggarwal B.B., and Yung W.K. PTEN enhances TNF-induced apoptosis through modulation of nuclear factor-kappaB signaling pathway in human glioma cells. Biochem Biophys Res Commun 3502 (2006) 463-471
55. Bergers G., and Benjamin L.E. Tumorigenesis and the angiogenic switch. Nat Rev Cancer 36 (2003) 401-410
56. O'Connor D.S., Schechner J.S., Adida C., et al. Control of apoptosis during angiogenesis by survivin expression in endothelial cells. Am J Pathol 1562 (2000) 393-398
57. Tran J., Master Z., Yu J.L., Rak J., Dumont D.J., and Kerbel R.S. A role for survivin in chemoresistance of endothelial cells mediated by VEGF. Proc Natl Acad Sci USA 997 (2002) 4349-4354
58. Tran J., Rak J., Sheehan C., et al. Marked induction of the IAP family antiapoptotic proteins survivin and XIAP by VEGF in vascular endothelial cells. Biochem Biophys Res Commun 2643 (1999) 781-788
59. Conway E.M., Zwerts F., Van Eygen V., et al. Survivin-dependent angiogenesis in ischemic brain: molecular mechanisms of hypoxia-induced up-regulation. Am J Pathol 1633 (2003) 935-946
60. Kawasaki H., Toyoda M., Shinohara H., et al. Expression of survivin correlates with apoptosis, proliferation, and angiogenesis during human colorectal tumorigenesis. Cancer 9111 (2001) 2026-2032
61. Blanc-Brude O.P., Mesri M., Wall N.R., Plescia J., Dohi T., and Altieri D.C. Therapeutic targeting of the survivin pathway in cancer: initiation of mitochondrial apoptosis and suppression of tumor-associated angiogenesis. Clin Cancer Res 97 (2003) 2683-2692
62. Tu S.P., Jiang X.H., Lin M.C., et al. Suppression of survivin expression inhibits in vivo tumorigenicity and angiogenesis in gastric cancer. Cancer Res 6322 (2003) 7724-7732
63. Altieri D.C. Survivin, versatile modulation of cell division and apoptosis in cancer. Oncogene 2253 (2003) 8581-8589
64. Fesik S.W. Promoting apoptosis as a strategy for cancer drug discovery. Nat Rev Cancer 511 (2005) 876-885
65. Pennati M., Folini M., and Zaffaroni N. Targeting survivin in cancer therapy: fulfilled promises and open questions. Carcinogenesis 286 (2007) 1133-1139
66. Asanuma K., Moriai R., Yajima T., et al. Survivin as a radioresistance factor in pancreatic cancer. Jpn J Cancer Res 9111 (2000) 1204-1209
67. Rodel C., Haas J., Groth A., Grabenbauer G.G., Sauer R., and Rodel F. Spontaneous and radiation-induced apoptosis in colorectal carcinoma cells with different intrinsic radiosensitivities: survivin as a radioresistance factor. Int J Radiat Oncol Biol Phys 555 (2003) 1341-1347
68. Chakravarti A., Zhai G.G., Zhang M., et al. Survivin enhances radiation resistance in primary human glioblastoma cells via caspase-independent mechanisms. Oncogene 2345 (2004) 7494-7506
69. Paik S., Shak S., Tang G., et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 35127 (2004) 2817-2826
70. Biroccio A., Leonetti C., and Zupi G. The future of antisense therapy: combination with anticancer treatments. Oncogene 2242 (2003) 6579-6588
71. He S.Q., Rehman H., Gong M.G., et al. Inhibiting survivin expression enhances TRAIL-induced tumoricidal activity in human hepatocellular carcinoma via cell cycle arrest. Cancer Biol Ther 68 (2007) 1247-1257
72. Kojima H., Iida M., Yaguchi Y., et al. Enhancement of Cisplatin sensitivity in squamous cell carcinoma of the head and neck transfected with a survivin antisense gene. Arch Otolaryngol - Head Neck Surg 1326 (2006) 682-685
73. Sharma H., Sen S., Lo Muzio L., Mariggio A., and Singh N. Antisense-mediated downregulation of anti-apoptotic proteins induces apoptosis and sensitizes head and neck squamous cell carcinoma cells to chemotherapy. Cancer Biol Ther 47 (2005) 720-727
74. Carter B.Z., Mak D.H., Schober W.D., et al. Regulation of survivin expression through Bcr-Abl/MAPK cascade: targeting survivin overcomes imatinib resistance and increases imatinib sensitivity in imatinib-responsive CML cells. Blood 1074 (2006) 1555-1563
75. Fisker N., Westergaard M., Hansen H.F., and Hansen J.B. Survivin mRNA antagonists using locked nucleic Acid, potential for molecular cancer therapy. Nucleos Nucleot Nucl Acid 2610 (2007) 1427-1430
76. Hayashi N., Asano K., Suzuki H., et al. Adenoviral infection of survivin antisense sensitizes prostate cancer cells to etoposide in vivo. Prostate 651 (2005) 10-19
77. Olie R.A., Simoes-Wust A.P., Baumann B., et al. A novel antisense oligonucleotide targeting survivin expression induces apoptosis and sensitizes lung cancer cells to chemotherapy. Cancer Res 6011 (2000) 2805-2809
78. Kim K.W., Mutter R.W., Willey C.D., et al. Inhibition of survivin and aurora B kinase sensitizes mesothelioma cells by enhancing mitotic arrests. Int J Rad Oncol Biol Phys 675 (2007) 1519-1525
79. Sah N.K., Munshi A., Hobbs M., Carter B.Z., Andreeff M., and Meyn R.E. Effect of downregulation of survivin expression on radiosensitivity of human epidermoid carcinoma cells. Int J Rad Oncol Biol Phys 663 (2006) 852-859
80. Kanwar J.R., Shen W.P., Kanwar R.K., Berg R.W., and Krissansen G.W. Effects of survivin antagonists on growth of established tumors and B7-1 immunogene therapy. J Natl Cancer Inst 9320 (2001) 1541-1552
81. Talbot D, Davies J, Callies S, et al. First human dose study evaluating safety and pharmacokinetics of LY2181308, an antisense oligonucleotide designed to inhibit survivin. In: ASCO annual meeting: J Clin Oncol: Abst No 3518, vol. 26; 2008.
82. Puerta-Fernandez E., Romero-Lopez C., Barroso-delJesus A., and Berzal-Herranz A. Ribozymes: recent advances in the development of RNA tools. FEMS Microbiol Rev 271 (2003) 75-97
83. Pennati M., Binda M., Colella G., et al. Radiosensitization of human melanoma cells by ribozyme-mediated inhibition of survivin expression. J Invest Dermatol 1204 (2003) 648-654
84. Pennati M., Colella G., Folini M., Citti L., Daidone M.G., and Zaffaroni N. Ribozyme-mediated attenuation of survivin expression sensitizes human melanoma cells to cisplatin-induced apoptosis. J Clin Invest 1092 (2002) 285-286
85. Pennati M., Binda M., De Cesare M., et al. Ribozyme-mediated down-regulation of survivin expression sensitizes human melanoma cells to topotecan in vitro and in vivo. Carcinogenesis 257 (2004) 1129-1136
86. Pennati M., Binda M., Colella G., et al. Ribozyme-mediated inhibition of survivin expression increases spontaneous and drug-induced apoptosis and decreases the tumorigenic potential of human prostate cancer cells. Oncogene 232 (2004) 386-394
87. Liu H., Guo S., Roll R., et al. Phi29 pRNA vector for efficient escort of hammerhead ribozyme targeting survivin in multiple cancer cells. Cancer Biol Ther 65 (2007) 697-704
88. Aagaard L., and Rossi J.J. RNAi therapeutics: principles, prospects and challenges. Adv Drug Deliv Rev 592-3 (2007) 75-86
89. Novina C.D., and Chabner B.A. RNA-directed therapy: the next step in the miRNA revolution. Oncologist 131 (2008) 1-3
90. Carvalho A., Carmena M., Sambade C., Earnshaw W.C., and Wheatley S.P. Survivin is required for stable checkpoint activation in taxol-treated HeLa cells. J Cell Sci 116 Pt 14 (2003) 2987-2998
91. Ling X., and Li F. Silencing of antiapoptotic survivin gene by multiple approaches of RNA interference technology. Biotechniques 363 450-4 (2004) 6-60
92. Ai Z., Yin L., Zhou X., et al. Inhibition of survivin reduces cell proliferation and induces apoptosis in human endometrial cancer. Cancer 1074 (2006) 746-756
93. Paduano F., Villa R., Pennati M., et al. Silencing of survivin gene by small interfering RNAs produces supra-additive growth suppression in combination with 17-allylamino-17-demethoxygeldanamycin in human prostate cancer cells. Mol Cancer Therapeut 51 (2006) 179-186
94. Nakao K., Hamasaki K., Ichikawa T., Arima K., Eguchi K., and Ishii N. Survivin downregulation by siRNA sensitizes human hepatoma cells to TRAIL-induced apoptosis. Oncol Report 162 (2006) 389-392
95. Lens S.M., Wolthuis R.M., Klompmaker R., et al. Survivin is required for a sustained spindle checkpoint arrest in response to lack of tension. EMBO J 2212 (2003) 2934-2947
96. Beltrami E., Plescia J., Wilkinson J.C., Duckett C.S., and Altieri D.C. Acute ablation of survivin uncovers p53-dependent mitotic checkpoint functions and control of mitochondrial apoptosis. J Biol Chem 2793 (2004) 2077-2084
97. Jiang G., Li J., Zeng Z., and Xian L. Lentivirus-mediated gene therapy by suppressing survivin in BALB/c nude mice bearing oral squamous cell carcinoma. Cancer Biol Ther 54 (2006) 435-440
98. Zhen H.N., Li L.W., Zhang W., et al. Short hairpin RNA targeting survivin inhibits growth and angiogenesis of glioma U251 cells. Int J Oncol 315 (2007) 1111-1117
99. Miao G.Y., Lu Q.M., and Zhang X.L. Downregulation of survivin by RNAi inhibits growth of human gastric carcinoma cells. World J Gastroenterol 138 (2007) 1170-1174
100. Song H., Xin X.Y., Xiao F., Wang D.T., Yue Q.H., and Han X. Survivin gene RNA interference inhibits proliferation, induces apoptosis, and enhances radiosensitivity in HeLa cells. Eur J Obstet Gynecol Reprod Biol 1361 (2008) 83-89
101. Huynh T., Walchli S., and Sioud M. Transcriptional targeting of small interfering RNAs into cancer cells. Biochem Biophys Res Commun 3504 (2006) 854-859
102. Kappler M., Taubert H., Bartel F., et al. Radiosensitization, after a combined treatment of survivin siRNA and irradiation, is correlated with the activation of caspases 3 and 7 in a wt-p53 sarcoma cell line, but not in a mt-p53 sarcoma cell line. Oncol Rep 131 (2005) 167-172
103. Yonesaka K., Tamura K., Kurata T., et al. Small interfering RNA targeting survivin sensitizes lung cancer cell with mutant p53 to adriamycin. Int J Cancer 1184 (2006) 812-820
104. Croci D.O., Cogno I.S., Vittar N.B., et al. Silencing survivin gene expression promotes apoptosis of human breast cancer cells through a caspase-independent pathway. J Cell Biochem 105 (2008) 381-390
105. Grossman D., McNiff J.M., Li F., and Altieri D.C. Expression and targeting of the apoptosis inhibitor, survivin, in human melanoma. J Invest Dermatol 1136 (1999) 1076-1081
106. Mesri M., Wall N.R., Li J., Kim R.W., and Altieri D.C. Cancer gene therapy using a survivin mutant adenovirus. J Clin Invest 1087 (2001) 981-990
107. Grossman D., Kim P.J., Schechner J.S., and Altieri D.C. Inhibition of melanoma tumor growth in vivo by survivin targeting. Proc Natl Acad Sci USA 982 (2001) 635-640
108. McKay T.R., Bell S., Tenev T., et al. Procaspase 3 expression in ovarian carcinoma cells increases survivin transcription which can be countered with a dominant-negative mutant, survivin T34A; a combination gene therapy strategy. Oncogene 2223 (2003) 3539-3547
109. Peng X.C., Yang L., Yang L.P., et al. Efficient inhibition of murine breast cancer growth and metastasis by gene transferred mouse survivin Thr34->Ala mutant. J Exp Clin Cancer Res 27 (2008) 46
110. Zhao J., Tenev T., Martins L.M., Downward J., and Lemoine N.R. The ubiquitin-proteasome pathway regulates survivin degradation in a cell cycle-dependent manner. J Cell Sci 113 Pt 23 (2000) 4363-4371
111. O'Connor D.S., Wall N.R., Porter A.C., and Altieri D.C. A p34(cdc2) survival checkpoint in cancer. Cancer Cell 21 (2002) 43-54
112. Altieri D.C. Validating survivin as a cancer therapeutic target. Nat Rev Cancer 31 (2003) 46-54
113. Zhang R., Wang T., Li K.N., et al. A survivin double point mutant has potent inhibitory effect on the growth of hepatocellular cancer cells. Cancer Biol Ther 74 (2008) 547-554
114. Nakahara T., Takeuchi M., Kinoyama I., et al. YM155, a novel small-molecule survivin suppressant, induces regression of established human hormone-refractory prostate tumor xenografts. Cancer Res 6717 (2007) 8014-8021
115. Cheng Q, Ling X, Wu J, et al. The novel small chemical molecule YM155 is a bona fide survivin transcription inhibitor and acts on the survivin proximal promoter region: inhibition of survivin promoter activity by YM155 is cell cycle-independent. In: Proc of the 99th annual meeting of the Am Assoc of Cancer Res: Abst No 1848; 2008.
116. Plescia J., Salz W., Xia F., et al. Rational design of shepherdin, a novel anticancer agent. Cancer Cell 75 (2005) 457-468
117. Chang C.C., Heller J.D., Kuo J., and Huang R.C. Tetra-O-methyl nordihydroguaiaretic acid induces growth arrest and cellular apoptosis by inhibiting Cdc2 and survivin expression. Proc Natl Acad Sci USA 10136 (2004) 13239-13244
118. Smolewski P. Terameprocol, a novel site-specific transcription inhibitor with anticancer activity. IDrugs 113 (2008) 204-214
119. Lopez R.A., Goodman A.B., Rhodes M., Blomberg J.A., and Heller J. The anticancer activity of the transcription inhibitor terameprocol (meso-tetra-O-methyl nordihydroguaiaretic acid) formulated for systemic administration. Anti-Cancer Drug 188 (2007) 933-939
120. Khanna N., Dalby R., Tan M., Arnold S., Stern J., and Frazer N. Phase I/II clinical safety studies of terameprocol vaginal ointment. Gynecol Oncol 1073 (2007) 554-562
121. Rosenberg S.A. Progress in human tumour immunology and immunotherapy. Nature 4116835 (2001) 380-384
122. Gattinoni L., Powell Jr. D.J., Rosenberg S.A., and Restifo N.P. Adoptive immunotherapy for cancer: building on success. Nat Rev Immunol 65 (2006) 383-393
123. Zhu K., Qin H., Cha S.C., et al. Survivin DNA vaccine generated specific antitumor effects in pancreatic carcinoma and lymphoma mouse models. Vaccine 2546 (2007) 7955-7961
124. Xiang R., Mizutani N., Luo Y., et al. A DNA vaccine targeting survivin combines apoptosis with suppression of angiogenesis in lung tumor eradication. Cancer Res 652 (2005) 553-561
125. Fuessel S., Meye A., Schmitz M., et al. Vaccination of hormone-refractory prostate cancer patients with peptide cocktail-loaded dendritic cells: results of a phase I clinical trial. Prostate 668 (2006) 811-821
126. Otto K., Andersen M.H., Eggert A., et al. Lack of toxicity of therapy-induced T cell responses against the universal tumour antigen survivin. Vaccine 237 (2005) 884-889
127. Wobser M., Keikavoussi P., Kunzmann V., Weininger M., Andersen M.H., and Becker J.C. Complete remission of liver metastasis of pancreatic cancer under vaccination with a HLA-A2 restricted peptide derived from the universal tumor antigen survivin. Cancer Immunol Immunother 5510 (2006) 1294-1298
128. Tsuruma T., Hata F., Torigoe T., et al. Phase I clinical study of anti-apoptosis protein, survivin-derived peptide vaccine therapy for patients with advanced or recurrent colorectal cancer. J Trans Med 21 (2004) 19
129. Tsuruma T., Iwayama Y., Ohmura T., et al. Clinical and immunological evaluation of anti-apoptosis protein, survivin-derived peptide vaccine in phase I clinical study for patients with advanced or recurrent breast cancer. J Trans Med 6 (2008) 24
130. Wang R, Wang X, Li B, et al. Tumor-specific adenovirus-mediated PUMA gene transfer using the survivin promoter enhances radiosensitivity of breast cancer cells in vitro and in vivo. Breast Cancer Res Treat 2008 Sep 13. Epub ahead of print.
131. Bao R., Connolly D.C., Murphy M., et al. Activation of cancer-specific gene expression by the survivin promoter. J Natl Cancer Inst 947 (2002) 522-528
132. Chen J.S., Liu J.C., Shen L., et al. Cancer-specific activation of the survivin promoter and its potential use in gene therapy. Cancer Gene Ther 1111 (2004) 740-747
133. Nandi S., Ulasov I.V., Tyler M.A., et al. Low-dose radiation enhances survivin-mediated virotherapy against malignant glioma stem cells. Cancer Res 6814 (2008) 5778-5784
134. Wang R., Lin F., Wang X., et al. The therapeutic potential of survivin promoter-driven siRNA on suppressing tumor growth and enhancing radiosensitivity of human cervical carcinoma cells via downregulating hTERT gene expression. Cancer Biol Ther 68 (2007) 1295-1301
135. Singh R.P., Tyagi A., Sharma G., Mohan S., and Agarwal R. Oral silibinin inhibits in vivo human bladder tumor xenograft growth involving down-regulation of survivin. Clin Cancer Res 141 (2008) 300-308
136. Tyagi A., Raina K., and Singh R.P. Et al. Chemopreventive effects of silymarin and silibinin on N-butyl-N-(4-hydroxybutyl) nitrosamine induced urinary bladder carcinogenesis in male ICR mice. Mol Cancer Ther 612 Pt 1 (2007) 3248-3255
137. Tyagi A.K., Agarwal C., Singh R.P., Shroyer K.R., Glode L.M., and Agarwal R. Silibinin down-regulates survivin protein and mRNA expression and causes caspases activation and apoptosis in human bladder transitional-cell papilloma RT4 cells. Biochem Biophys Res Commun 3124 (2003) 1178-1184
138. Wall N.R., O'Connor D.S., Plescia J., Pommier Y., and Altieri D.C. Suppression of survivin phosphorylation on Thr34 by flavopiridol enhances tumor cell apoptosis. Cancer Res 631 (2003) 230-235
139. Harikumar K.B., and Aggarwal B.B. Resveratrol: a multitargeted agent for age-associated chronic diseases. Cell Cycle (Georgetown, Tex) 78 (2008) 1020-1035
140. Fulda S., and Debatin K.M. Sensitization for anticancer drug-induced apoptosis by the chemopreventive agent resveratrol. Oncogene 2340 (2004) 6702-6711
141. Fulda S., and Debatin K.M. Sensitization for tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by the chemopreventive agent resveratrol. Cancer Res 641 (2004) 337-346
142. Fulda S., and Debatin K.M. Resveratrol-mediated sensitisation to TRAIL-induced apoptosis depends on death receptor and mitochondrial signalling. Eur J Cancer 415 (2005) 786-798
143. Zhang T., Fields J.Z., Ehrlich S.M., and Boman B.M. The chemopreventive agent sulindac attenuates expression of the antiapoptotic protein survivin in colorectal carcinoma cells. J Pharmacol Experiment Therapeut 3082 (2004) 434-437
144. Sakoguchi-Okada N., Takahashi-Yanaga F., Fukada K., et al. Celecoxib inhibits the expression of survivin via the suppression of promoter activity in human colon cancer cells. Biochem Pharmacol 739 (2007) 1318-1329
145. Rayman M.P. Selenium in cancer prevention: a review of the evidence and mechanism of action. Proc Nutr Society 644 (2005) 527-542
146. Chun J.Y., Hu Y., Pinder E., Wu J., Li F., and Gao A.C. Selenium inhibition of survivin expression by preventing Sp1 binding to its promoter. Mol Cancer Ther 69 (2007) 2572-2580
147. National Cancer Institute. The SELECT prostate cancer prevention trial; 2008. Available from: [accessed 28.10.08].
148. Vogel V.G., Costantino J.P., Wickerham D.L., et al. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA 29523 (2006) 2727-2741
149. Nakayama Y., Sakamoto H., Satoh K., and Yamamoto T. Tamoxifen and gonadal steroids inhibit colon cancer growth in association with inhibition of thymidylate synthase, survivin and telomerase expression through estrogen receptor beta mediated system. Cancer Lett 1611 (2000) 63-71
150. Fukuda S., and Pelus L.M. Survivin, a cancer target with an emerging role in normal adult tissues. Mol Cancer Ther 55 (2006) 1087-1098
151. Chiou S.K., Moon W.S., Jones M.K., and Tarnawski A.S. Survivin expression in the stomach: implications for mucosal integrity and protection. Biochem Biophys Res Commun 3052 (2003) 374-379
152. Marconi A., Dallaglio K., Lotti R., et al. Survivin identifies keratinocyte stem cells and is downregulated by anti-beta1 integrin during anoikis. Stem Cells (Dayton, Ohio) 251 (2007) 149-155
153. Frost M., Jarboe E.A., Orlicky D., et al. Immunohistochemical localization of survivin in benign cervical mucosa, cervical dysplasia, and invasive squamous cell carcinoma. Am J Clin Pathol 1175 (2002) 738-744
154. Tolcher AW, Antonia S, Lewis LD, et al. A phase I study of YM155, a novel survivin suppressant, administered by 168 hours continuous infusion to patients with advanced solid tumors. In: Proc Am Soc Clin Oncol 42nd annual meeting; 2006.
155. Nakagawa K, Satoh T, Okamoto I, et al. Phase I study of YM155, a first-in-class survivin suppressant, in patients with advanced solid tumors in Japan. In: 2007 ASCO annual meeting Proc (J Clin Oncol); 2007.
156. Miranda M.B., Dyer K.F., Grandis J.R., and Johnson D.E. Differential activation of apoptosis regulatory pathways during monocytic vs granulocytic differentiation: a requirement for Bcl-X(L)and XIAP in the prolonged survival of monocytic cells. Leukemia 172 (2003) 390-400
157. Cong X.L., and Han Z.C. Survivin and leukemia. Int J Hematol 803 (2004) 232-238
158. Leung C.G., Xu Y., Mularski B., Liu H., Gurbuxani S., and Crispino J.D. Requirements for survivin in terminal differentiation of erythroid cells and maintenance of hematopoietic stem and progenitor cells. J Exp Med 2047 (2007) 1603-1611
159. Fukuda S., and Pelus L.M. Regulation of the inhibitor-of-apoptosis family member survivin in normal cord blood and bone marrow CD34(+) cells by hematopoietic growth factors: implication of survivin expression in normal hematopoiesis. Blood 987 (2001) 2091-2100
160. Fukuda S., Foster R.G., Porter S.B., and Pelus L.M. The antiapoptosis protein survivin is associated with cell cycle entry of normal cord blood CD34(+) cells and modulates cell cycle and proliferation of mouse hematopoietic progenitor cells. Blood 1007 (2002) 2463-2471
161. Fukuda S., Mantel C.R., and Pelus L.M. Survivin regulates hematopoietic progenitor cell proliferation through p21WAF1/Cip1-dependent and -independent pathways. Blood 1031 (2004) 120-127
162. Visvader J.E., and Lindeman G.J. Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat Rev Cancer 810 (2008) 755-768
163. Pardal R., Clarke M.F., and Morrison S.J. Applying the principles of stem-cell biology to cancer. Nat Rev Cancer 312 (2003) 895-902
164. Fodde R., and Brabletz T. Wnt/beta-catenin signaling in cancer stemness and malignant behavior. Curr Opin Cell Biol 192 (2007) 150-158
165. Lee C.W., Raskett C.M., Prudovsky I., and Altieri D.C. Molecular dependence of estrogen receptor-negative breast cancer on a notch-survivin signaling axis. Cancer Res 6813 (2008) 5273-5281
166. Klaus A., and Birchmeier W. Wnt signalling and its impact on development and cancer. Nat Rev Cancer 85 (2008) 387-398
167. Radtke F., and Raj K. The role of Notch in tumorigenesis: oncogene or tumour suppressor?. Nat Rev Cancer 310 (2003) 756-767
168. Harlin H., Reffey S.B., Duckett C.S., Lindsten T., and Thompson C.B. Characterization of XIAP-deficient mice. Mol Cell Biol 2110 (2001) 3604-3608
169. Konopleva M., Tari A.M., Estrov Z., et al. Liposomal Bcl-2 antisense oligonucleotides enhance proliferation, sensitize acute myeloid leukemia to cytosine-arabinoside, and induce apoptosis independent of other antiapoptotic proteins. Blood 9512 (2000) 3929-3938
170. Wang H.W., Sharp T.V., Koumi A., Koentges G., and Boshoff C. Characterization of an anti-apoptotic glycoprotein encoded by Kaposi's sarcoma-associated herpesvirus which resembles a spliced variant of human survivin. EMBO J 2111 (2002) 2602-2615
171. Zhu N., Gu L., Findley H.W., Li F., and Zhou M. An alternatively spliced survivin variant is positively regulated by p53 and sensitizes leukemia cells to chemotherapy. Oncogene 2345 (2004) 7545-7551
172. Ling X., Cheng Q., Black J.D., and Li F. Forced expression of survivin-2B abrogates mitotic cells and induces mitochondria-dependent apoptosis by blockade of tubulin polymerization and modulation of Bcl-2, Bax, and survivin. J Biol Chem 28237 (2007) 27204-27214
173. Kappler M., Rot S., Taubert H., et al. The effects of knockdown of wild-type survivin, survivin-2B or survivin-delta3 on the radiosensitization in a soft tissue sarcoma cells in vitro under different oxygen conditions. Cancer Gene Ther 1412 (2007) 994-1001
174. Wuttig D., Kunze D., Fuessel S., et al. Are overexpressed alternative survivin transcripts in human bladder cancer suitable targets for siRNA-mediated in vitro inhibition?. Int J Oncol 306 (2007) 1317-1324